Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novartis AG

111.04
+0.50000.45%
Volume:943.32K
Turnover:105.04M
Market Cap:219.31B
PE:18.92
High:111.95
Open:111.01
Low:110.83
Close:110.54
Loading ...

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

Dow Jones
·
10 Apr

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update

Dow Jones
·
09 Apr

Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ

Dow Jones
·
09 Apr

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Dow Jones
·
09 Apr

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

Dow Jones
·
09 Apr

Trump teases targeted tariffs on overseas drug manufacturers

Dow Jones
·
09 Apr

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

Zacks
·
04 Apr

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

Benzinga
·
04 Apr

Novartis Gets FDA Accelerated Approval for Vanrafia

MT Newswires Live
·
03 Apr

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

Dow Jones
·
03 Apr

Novartis gets FDA accelerated approval for Vanrafia

TIPRANKS
·
03 Apr

Big Pharma Avoids Worst-Case Tariff Scenario -- WSJ

Dow Jones
·
03 Apr

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks
·
02 Apr

Novartis AG Falls Monday, Outperforms Market

Dow Jones
·
01 Apr

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Zacks
·
31 Mar

Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development

MT Newswires Live
·
31 Mar

Novartis Gets FDA Approval for Expanded Pluvicto Indication

MT Newswires Live
·
29 Mar

FDA approves Novartis radioligand therapy Pluvicto for earlier use in mCRPC

TIPRANKS
·
29 Mar

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

GlobeNewswire
·
29 Mar

Novus Holdings Says TRP Withdraws Approval Of Co's Firm Intention Announcement

T-Reuters
·
28 Mar